GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intercure Ltd (TSX:INCR.U) » Definitions » EV-to-EBITDA

Intercure (TSX:INCR.U) EV-to-EBITDA : (As of Jun. 29, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Intercure EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Intercure's enterprise value is $89.61 Mil. Intercure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil. Therefore, Intercure's EV-to-EBITDA for today is .

The historical rank and industry rank for Intercure's EV-to-EBITDA or its related term are showing as below:

TSX:INCR.U' s EV-to-EBITDA Range Over the Past 10 Years
Min: -139.83   Med: 10.62   Max: 38.64
Current: -7.94

During the past 13 years, the highest EV-to-EBITDA of Intercure was 38.64. The lowest was -139.83. And the median was 10.62.

TSX:INCR.U's EV-to-EBITDA is ranked worse than
100% of 731 companies
in the Drug Manufacturers industry
Industry Median: 13.8 vs TSX:INCR.U: -7.94

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-29), Intercure's stock price is $1.53. Intercure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.000. Therefore, Intercure's PE Ratio (TTM) for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Intercure EV-to-EBITDA Historical Data

The historical data trend for Intercure's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercure EV-to-EBITDA Chart

Intercure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.88 29.64 7.86 -12.36 -7.55

Intercure Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.17 10.23 -12.36 - -7.55

Competitive Comparison of Intercure's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intercure's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intercure's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Intercure's EV-to-EBITDA falls into.


;
;

Intercure EV-to-EBITDA Calculation

Intercure's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=89.614/0
=

Intercure's current Enterprise Value is $89.61 Mil.
Intercure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intercure  (TSX:INCR.U) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Intercure's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.53/0.000
=N/A

Intercure's share price for today is $1.53.
Intercure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Intercure EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Intercure's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Intercure Business Description

Traded in Other Exchanges
Address
85 Medinat ha-Yehudim Street, Herzliya, ISR, 4676670
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

Intercure Headlines

No Headlines